Blab AI
Rice Bioengineering Professor Michael King Appointed to Texas AI-Cancer Advisory Committee
When Texas announced the launch of a new advisory panel on artificial intelligence, the focus immediately shifted to Rice University’s Michael King. On August 19 2026, King was named a founding member of the Cancer Prevention and Research Institute of Texas (CPRIT) Advisory Committee on Artificial Intelligence (ACAI). The panel will advise CPRIT on how AI can accelerate cancer research, prevention, and grant‑making while safeguarding responsible and ethical use.
CPRIT, a state agency financed through Texas bonds, ranks as the country’s second‑largest public cancer research funder. Since its 2007 inception, the agency has awarded more than $4.2 billion to Texas institutions, backing academic studies, prevention programs, and product development. A 2019 voter initiative added an extra $3 billion, raising the total state commitment to $6 billion.
King, the E.D. Butcher Professor of Bioengineering and a CPRIT Scholar, has spent two decades investigating how cancer and immune cells move through the bloodstream and respond to mechanical forces such as fluid flow and focused ultrasound. His laboratory constructs three‑dimensional models of blood‑borne metastasis, enabling researchers to observe cancer cell migration and test therapeutic interventions in a controlled environment.
The ACAI will comprise 11 members drawn from Texas’s academic institutions, including El Paso, Austin, College Station, Houston, and Dallas. CPRIT’s Oversight Committee approved the panel’s creation on the same day it was announced. Its mandate is broad: it will evaluate emerging computational tools, assess how AI can be integrated into diverse cancer research efforts, and help shape policies that balance innovation with rigorous science.
King’s appointment dovetails with Rice’s 10‑year strategic plan, Momentous, which lists responsible AI as a key catalyst for the university’s health‑innovation agenda. His expertise in bioengineering and AI will help the committee understand both the technical and ethical dimensions of applying machine learning to complex biological data.
According to the CPRIT website, the agency’s advisory committees guide higher education, childhood cancers, and other priority areas. The new AI committee follows a trend of state agencies recognizing AI’s growing influence in biomedical research. By uniting experts from multiple Texas universities, the panel aims to craft a statewide framework for AI‑driven cancer research that can inform grant decisions and research priorities.
For Texas researchers who rely on CPRIT funding, the committee’s work will have tangible implications. By clarifying best practices for AI use, the panel can help scientists design studies that are reproducible, transparent, and ethically sound. It can also spotlight gaps where additional training or infrastructure is needed, such as secure data‑sharing platforms or computational resources.
In its first meeting, the ACAI is expected to review current AI projects funded by CPRIT, assess the readiness of Texas institutions to adopt AI tools, and develop guidelines for responsible AI deployment in cancer research. The committee will also consider how AI can support the state’s broader cancer prevention and treatment goals.
As Texas continues to invest heavily in cancer research, the ACAI’s recommendations could shape the next wave of AI‑enabled discoveries. The panel’s findings will be released in the coming months, and CPRIT plans to incorporate them into its upcoming grant cycle. The work will also inform discussions with federal agencies and private partners interested in advancing AI in oncology.
In summary, Michael King’s selection to the ACAI marks a significant step toward integrating AI into Texas’s cancer research ecosystem. The committee’s guidance will help ensure that AI tools are applied responsibly and effectively, supporting the state’s commitment to reducing cancer incidence and improving patient outcomes.
CPRIT, a state agency financed through Texas bonds, ranks as the country’s second‑largest public cancer research funder. Since its 2007 inception, the agency has awarded more than $4.2 billion to Texas institutions, backing academic studies, prevention programs, and product development. A 2019 voter initiative added an extra $3 billion, raising the total state commitment to $6 billion.
King, the E.D. Butcher Professor of Bioengineering and a CPRIT Scholar, has spent two decades investigating how cancer and immune cells move through the bloodstream and respond to mechanical forces such as fluid flow and focused ultrasound. His laboratory constructs three‑dimensional models of blood‑borne metastasis, enabling researchers to observe cancer cell migration and test therapeutic interventions in a controlled environment.
The ACAI will comprise 11 members drawn from Texas’s academic institutions, including El Paso, Austin, College Station, Houston, and Dallas. CPRIT’s Oversight Committee approved the panel’s creation on the same day it was announced. Its mandate is broad: it will evaluate emerging computational tools, assess how AI can be integrated into diverse cancer research efforts, and help shape policies that balance innovation with rigorous science.
King’s appointment dovetails with Rice’s 10‑year strategic plan, Momentous, which lists responsible AI as a key catalyst for the university’s health‑innovation agenda. His expertise in bioengineering and AI will help the committee understand both the technical and ethical dimensions of applying machine learning to complex biological data.
According to the CPRIT website, the agency’s advisory committees guide higher education, childhood cancers, and other priority areas. The new AI committee follows a trend of state agencies recognizing AI’s growing influence in biomedical research. By uniting experts from multiple Texas universities, the panel aims to craft a statewide framework for AI‑driven cancer research that can inform grant decisions and research priorities.
For Texas researchers who rely on CPRIT funding, the committee’s work will have tangible implications. By clarifying best practices for AI use, the panel can help scientists design studies that are reproducible, transparent, and ethically sound. It can also spotlight gaps where additional training or infrastructure is needed, such as secure data‑sharing platforms or computational resources.
In its first meeting, the ACAI is expected to review current AI projects funded by CPRIT, assess the readiness of Texas institutions to adopt AI tools, and develop guidelines for responsible AI deployment in cancer research. The committee will also consider how AI can support the state’s broader cancer prevention and treatment goals.
As Texas continues to invest heavily in cancer research, the ACAI’s recommendations could shape the next wave of AI‑enabled discoveries. The panel’s findings will be released in the coming months, and CPRIT plans to incorporate them into its upcoming grant cycle. The work will also inform discussions with federal agencies and private partners interested in advancing AI in oncology.
In summary, Michael King’s selection to the ACAI marks a significant step toward integrating AI into Texas’s cancer research ecosystem. The committee’s guidance will help ensure that AI tools are applied responsibly and effectively, supporting the state’s commitment to reducing cancer incidence and improving patient outcomes.
